Navigation Links
Phase 2a Diarrhea Predominant Irritable Bowel Syndrome Results from,2006 Presented at Digestive Disease Week in Washington, D.C.

SOUTH SAN FRANCISCO, Calif., May 23, 2007 /PRNewswire-FirstCall/ -- Napo Pharmaceuticals, Inc., , which focuses on the development and commercialization of proprietary pharmaceuticals for the global marketplace in collaboration with local partners, announced that Trine Pharmaceuticals, Inc. ("Trine") is presenting a poster detailing the results of a Phase 2a study conducted in 2006 for crofelemer for diarrhoea predominant irritable bowel syndrome (d-IBS) today at Digestive Disease Week in Washington, D.C. Trine licensed crofelemer for the d-IBS indication from Napo in June 2004. Trine has worldwide development and commercialization rights to crofelemer for d-IBS. The objective of the trial was to evaluate the safety and efficacy of crofelemer in men and women with d-IBS.

The trial was designed as a randomized double-blind placebo-controlled, dose-ranging (placebo, 125 mg, 250 mg, and 500 mg bid) study over a 12-week treatment period in 246 patients with d-IBS (Rome II criteria), including both males and females, whose average age was 50 years old.

IBS symptoms (pain, urgency, stool frequency and consistency, and adequate relief) were self-reported by the patients via an interactive voice response system (IVRS). Patients needed to exhibit active disease during the two-week baseline period as defined by a mean daily stool frequency greater than or equal to 2/day, pain score greater than or equal to 1 and stool consistency greater than or equal to 3 (5-point Lickert scale for pain and consistency) to be enrolled. Patients received treatment for 12 weeks followed by a two-week treatment free period.

Results: The 125 mg bid of crofelemer exhibited a consistent response during each month among most efficacy endpoints in women with d-IBS (see table) reaching statistical significance (p<0.05) for pain. Crofelemer had little effect on the stool consistency score, though there was a trend toward redu
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

Post Your Comments:
(Date:11/9/2009)..., PRINCETON, N.J., Nov. 9 /PRNewswire-FirstCall/...nagement will present at the Sixth Annual Lazard C...ce will be held at the St Regis Hotel in New York ... Pharmasset,s President and Chief Executive Office...esday, November 18, 2009 at 3:45 PM (ET). ,, To...
(Date:11/9/2009)...F LAKE, N.J., Nov. 9 Par...y announced that it has extended the expiration da...sly announced "Modified Dutch Auction" tender offe... up to $65,000,000 aggregate principal amount, or ...5% Senior Subordinated Convertible Notes due 2010....
(Date:11/9/2009)..., Nov. 9 MISSION Skincare®, t...tar Serena Williams, soccer professional Mia Hamm,... "Active Lifestyle Skincare Destinations" in the b...ons across the country beginning this week. Stocke...ducts, MISSION and CVS/pharmacy have set out to es...
Breaking Medicine Technology:Pharmasset to Present at Lazard Capital Markets Healthcare Conference 2Pharmasset to Present at Lazard Capital Markets Healthcare Conference 3Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note 2Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note 3Glamour Magazine Woman of the Year and MISSION Skincare Co-Founder, Serena Williams, Teams Up with CVS/pharmacy to Launch National 'Active Lifestyle Skincare Destinations' 2Glamour Magazine Woman of the Year and MISSION Skincare Co-Founder, Serena Williams, Teams Up with CVS/pharmacy to Launch National 'Active Lifestyle Skincare Destinations' 3People With Huntingtons Report Discrimination 48766 1People With Huntingtons Report Discrimination 48766 2People With Huntingtons Report Discrimination 48766 3Salient Mobility Launches the Text For a Cause 28TM 29 Campaign in Raising Awareness Through Wireless Health Tips 48763 1Salient Mobility Launches the Text For a Cause 28TM 29 Campaign in Raising Awareness Through Wireless Health Tips 48763 2RA individuals from lower GDP countries keep working despite worse symptoms than richer countries 48759 1RA individuals from lower GDP countries keep working despite worse symptoms than richer countries 48759 2
...l phase I trial,AFF001, AFFiRiS GmbH has now recru...ial. The trial aims to investigate the tolerabilit...(AFFITOPE AD01). In the trial, all,patients have n...olerated,the vaccine extremely well. The treatment...nthly intervals and is due to be fully completed b...
...maceuticals, Inc. (Nasdaq: MAPP ) announced that ...ng the safety, tolerability and,pharmacokinetics o...e July,issue of Current Medical Research and Opini...orally inhaled and self-administered therapy, as a...ults, which were first announced last year, demons...
Other Medicine Technology:AFFiRiS: Milestone Reached in Clinical Trial of Alzheimer's Vaccine 2AFFiRiS: Milestone Reached in Clinical Trial of Alzheimer's Vaccine 3MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion 2MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion 3MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion 4
(Date:11/9/2009)... Study in mice reports success with drugs that in...lthDay News) -- Two drugs used to treat breast can... mice, according to a new study. , The drugs al...vagina, and prevented the onset of cancer in mice ...drug fulvestrant and the breast cancer/osteoporosi...
(Date:11/9/2009)... Plavix helped men and women almost equally, stud...News) -- The widely used clot-dissolving drug Plav...in men, an analysis of major clinical trials has f...confident in treating both men and women with this... director of cardiovascular thrombosis at New York...
(Date:11/9/2009)... , Networking is everybod...s it means Money. StaffingClub.com enables Recruit...of contacts to connect, share, communicate and clo... Seekers to post their profiles and network with r...mber 9, 2009 -- Current Job Market forces everyone...
(Date:11/9/2009)... Therapy to improve letter formation could boost ... Nov. 9 (HealthDay News) -- Autistic children are ...g trouble forming letters, than those without auti...8 children, aged 8 to 13. Half of the study partic...e children scored within the normal range for perc...
(Date:11/9/2009)... Rabbits implanted with new cells regained sexual...v. 9 (HealthDay News) -- Researchers were able to ...nises by growing new penile tissue in the lab and ...human application is a ways off, researchers say t... erectile dysfunction in men. , "We were able t...
Breaking Medicine News(10 mins):Health News:Breast Cancer Drugs May Fight Cervical Cancer, Too 2Health News:No Gender Gap Found for Clot-Busting Drug 2Health News:No Gender Gap Found for Clot-Busting Drug 3Health News:Launching StaffingClub.com, a New Online Networking Platform for Recruiting and Staffing Professionals 2Health News:Handwriting Skills May Lag in Kids With Autism 2Health News:Scientists Grow New Penile Tissue in the Lab 2Health News:Scientists Grow New Penile Tissue in the Lab 3
...ffected the dental health of the expectant mother....ammations can lead to a condition of preeclampsia ...ic dental inflammation and periodontal infection, ...moking, etc. The basic reason for setting in the d...
...nic, progressive disorder where there is a loss of...rug // alendronate if taken daily for 10 years can...ugs, such as alendronate, have been used for years...he drug for the next two years. Then for the next ...
...that fetal cell transplantation for patients with ...id of their medications altogether.// Parkinso... impairs mobility. Patients with Parkinson’s lack ...st dopamine-producing cells to help restore moveme...
...ommon sleep disorder leaves nearly millions groggy...is that // the tricks they do to get to sleep may ...alists say as we age, biological changes gradually...to do is to cut out caffeine after noon and to ski...
... recent study researchers say annual flu vaccines ... on // hospitalizations, respiratory tract infecti...pecially true for children who received an inactiv...r children under age 2 who received the inactivate...
...Society's 140th Midwinter Meeting that begins in U...orld over can take a peek to some very innovative ...isplay there. The convention is also one of the la...s that automatically dispenses toothpaste, and a c...
Other Medicine News:
Castroviejo Suture Forceps
deJuan Pic Forceps - Black
Thomas Long Subretinal Forceps
Olk Membrane Peeler
Medicine Products: